<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2325">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130892</url>
  </required_header>
  <id_info>
    <org_study_id>NLRP3-CRP</org_study_id>
    <nct_id>NCT05130892</nct_id>
  </id_info>
  <brief_title>Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI</brief_title>
  <official_title>Effect of Inflammasome Inhibitor on High-sensitivity C-reactive Protein in Patients After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (CAD) comprises the major contributor to a global epidemic of&#xD;
      cardiovascular disease. Patients with CAD undergoing percutaneous coronary intervention (PCI)&#xD;
      have a high-risk for adverse clinical outcomes.&#xD;
&#xD;
      Residual inflammatory risk (RIR) in patients with CAD after standardized treatment is the&#xD;
      main cause of adverse events such as recurrent myocardial infarction, stroke, and death,&#xD;
      which has gained much interest in recent years. Inflammation plays an important role in the&#xD;
      development of CAD. However, several randomized controlled clinical studies (RCT) of&#xD;
      anti-inflammatory treatments ended in failure previously. Since 2017, the success of three&#xD;
      large-scale RCTs (CANTOS, COLCOT and LoDoCo2) points to targeting the NLRP3 - IL-1 β- IL-6&#xD;
      pathway for anti-inflammatory treatment of CAD. The inhibition of this pathway eventually&#xD;
      leads to the decrease of high-sensitivity C-reactive protein (hsCRP), consistent with an&#xD;
      anti-inflammatory effect. Therefore, the change of hsCRP may serve as a biomarker to screen&#xD;
      anti-inflammatory drugs in this pathway.&#xD;
&#xD;
      Targeting the NLRP3 - IL-1 β- IL-6 pathway with monoclonal antibodies is limited by high&#xD;
      prices of the biological agents. Thus, researchers focused on the upstream molecule NLRP3.&#xD;
      Currently, NLRP3 inhibitors that are clinically available include colchicine , tranilast and&#xD;
      oridonin. Although several studies have indicated the effective effects of colchicine in CAD,&#xD;
      the other two NLRP3 inhibitors lack sufficient data on anti-inflammatory treatment of CAD.&#xD;
      Therefore, we intend to use NLRP3 inhibitors (colchicine, tranilast and oridonin) to treat&#xD;
      patients after PCI for 4 weeks, compare the changes of hsCRP, and explore the effectiveness&#xD;
      and safety of these different drugs, and screen the optimal anti-inflammatory drugs for&#xD;
      coronary heart disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in hsCRP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage change in hsCRP at the end of 4 weeks compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE (composite endpoint of all-cause death, nonfatal myocardial infarction, nonfatal stroke, revascularization due to ischemia, or hospitalization due to unstable angina pectoris)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Time to occurrence of MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>4 weeks</time_frame>
    <description>Time to occurrence of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics analysis</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proteomics analysis using cardiovascular II/III panel by Olink company</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>NLRP3</condition>
  <condition>hsCRP</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Colchicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet (0.5mg) / time, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranilast group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule (0.1g) / time, 3 times a day;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oridonin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets (0.5g) / time, 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-intervention group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>1 tablet (0.5mg) / time, once a day</description>
    <arm_group_label>Colchicine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranilast</intervention_name>
    <description>1 capsule (0.1g) / time, 3 times a day</description>
    <arm_group_label>Tranilast group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oridonin</intervention_name>
    <description>2 tablets (0.5g) / time, 3 times a day;</description>
    <arm_group_label>Oridonin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily participate, and sign the informed consent form;&#xD;
&#xD;
          2. Age ≥ 18 and ≤ 80 years, regardless of sex;&#xD;
&#xD;
          3. Patients after completion of planned percutaneous coronary intervention for 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to colchicine, tranilast or oridonin;&#xD;
&#xD;
          2. Taking colchicine, tranilast or oridonin before the screening period (10 days);&#xD;
&#xD;
          3. Abnormal liver function (ALT &gt; 3 times the upper limit of normal value);&#xD;
&#xD;
          4. Abnormal renal function (creatinine clearance &lt; 45 ml / min);&#xD;
&#xD;
          5. Thrombocytopenia (PLT &lt; 100g / L);&#xD;
&#xD;
          6. Uncontrolled infectious diseases;&#xD;
&#xD;
          7. Complicated with immune diseases or immune related diseases such as systemic lupus&#xD;
             erythematosus, asthma, inflammatory bowel disease, gout, and malignant tumor, etc.&#xD;
&#xD;
          8. Nonsteroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic&#xD;
             drugs been taken;&#xD;
&#xD;
          9. History of surgery within 6 months before the screening period;&#xD;
&#xD;
         10. Pregnant women, lactating women or women of childbearing age who do not use effective&#xD;
             contraceptives;&#xD;
&#xD;
         11. Other circumstances in which the investigator judges that the patient is not suitable&#xD;
             to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Cheng, Doctor</last_name>
      <phone>+8602785726011</phone>
      <email>nathancx@hust.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiang Cheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Miao, Doctor</last_name>
      <phone>+8613995562434</phone>
      <email>yumiaodavid@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiang Cheng</investigator_full_name>
    <investigator_title>Director of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranilast</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

